Immunomodulatory effects of targeted radionuclide therapy

Constanzo, Julie; Bouden, Y.; Godry, L.; Kotzki, Pierre‐Olivier; Deshayes, Emmanuel; Pouget, Jean-Pierre

doi:10.1016/bs.ircmb.2023.02.001

Cited by 3 publications

(2 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding internal selective RT, absorbed dose is approximatively 100 to 1000 lower than external RT however with a significantly longer exposure time due to α and β radioisotopes [ 63 ]. Pre-clinical and clinical findings with low irradiation doses indicated activation of the immune system via the cGAS-STING pathway [ 64 ]. This pathway results in type I interferon (as IFN-β) expression, activating T cells and leading to extracellular vesicles release.…”

Section: Immune Modulation Post-radiation Therapiesmentioning

confidence: 99%

Non-targeted effects of radiation therapy for glioblastoma

Lerouge,

Ruch,

Pierson

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Immune Modulation Post-radiation Therapiesmentioning

confidence: 99%

Non-targeted effects of radiation therapy for glioblastoma

Lerouge,

Ruch,

Pierson

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Similar to EBRT, RPT may also influence the immune system's response to tumors (7,8,(80)(81)(82)(83)(84)(85)(86). This can be achieved through the direct irradiation of immune cells in the TME or indirectly (87) (Figure 3).…”

Section: Immunomodulatory Effects Of Rptmentioning

confidence: 99%

Immunological effects of radiopharmaceutical therapy

Shea,

Idrissou,

Torres

et al. 2024

Front. Nucl. Med.

View full text Add to dashboard Cite

Radiation therapy (RT) is a pillar of cancer therapy used in more than half of all cancer patients. Clinically, RT is mostly delivered as external beam radiation therapy (EBRT). However, the scope of EBRT is limited in the metastatic setting when all sites of disease need to be irradiated. Such limitation is attributed to radiation-induced toxicities including bone marrow and hematologic toxicities, ensuing from a large EBRT field. Radiopharmaceutical therapy (RPT) has emerged as an alternative to EBRT for the irradiation of all sites of metastatic disease. While RPT can reduce tumor burden, it can also impact the immune system and anti-tumor immunity. Understanding these effects is crucial for predicting and managing treatment-related hematological toxicities and optimizing their integration with other therapeutic modalities such as immunotherapies. Herein, we review the immunomodulatory effects of α- and β-particle emitter-based RPT on various immune cell lines including CD8+ and CD4+ T cells, natural killer (NK) cells, and regulatory T (Treg) cells. We briefly discuss Auger electron-emitter (AEE) based RPT and lastly, we highlight the combination of RPT with immune checkpoint inhibitors, which may offer potential therapeutic synergies for patients with metastatic cancers.

show abstract